Advertisement
YOU ARE HERE: KY3 HomeCollections

FDA considers taking one obesity drug off the market and putting another on the market.

Meridia under scrutiny and Lorcaserin considered for new release.

September 15, 2010|Lisa Rose | KY3 News Anchor

Drugs to treat obesity under review this week by the food and drug administration.  The F-D-A may vote to recommend a *new* drug to fight obesity.    

And it may vote to yank another one entirely off the market.  When a healthy diet and exercise aren't enough to reach weight-loss goals -- millions of Americans turn to medication.  But one obesity drug -- Meridia -- has been linked to higher rates of heart attacks and strokes in patients with heart disease. 

“A lot of times people who are overweight may have unrecognized hypertension or heart disease maybe if they don't go to the doctor regularly," said Dr. Leena Khaitan, with Case Medical Center in Cleveland, Ohio.  Today, an F-D-A panel of experts will weigh Meridia's risks and benefits...and discuss whether it should stay on the market or be pulled. 

On Thursday – F-D-A advisors will consider whether an experimental drug called Lorcaserin should be placed on the market. Researchers say it had few side effects in clinical trials -- where patients lost an average of 17 pounds over a year.  And researchers say it improved health in other ways. 

Advertisement

"Things like blood pressure, blood sugar, inflammation -- all of these markers improved in the Lorcaserin studies," said Dr. Louis Aronne, with New York-Presbyterian Hospital.  If approved -- Lorcaserin would be the first new prescription weight-loss drug in a decade.  

F-D-A advisors are scheduled to review another weight loss drug called Contrave in December.  Contrave is a combination of an anti-depressant and another drug used for alcohol addiction.

KY3 Articles
|
|
|